Key Details
Price
$265.28Annual Revenue
$1.70 BAnnual EPS
$2.94Annual ROE
34.12%Beta
0.87Events Calendar
Next earnings date:
Feb 21, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Feb 22, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
No matter if you invest in value, growth, or momentum stocks, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the best features of the Zacks Premium research service.
PODD stock remains a focus for investors because of its strong advancements with Omnipod 5 and its significant opportunities in the diabetes market.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology with its Omnipod® products, has successfully protected its intellectual property against EOFlow Co., Ltd. in federal court. Following a four-week trial in the U.S. District Court for the District of Massachusetts, the jury ruled in favor of Insulet.
Are you looking for ways to choose powerful stocks that can outperform the market for your investment portfolio? The Zacks Style Scores can help you with that.
Insulet's Omnipod 5 System can now work with Abbott's FreeStyle Libre 2 Plus Sensor in the United States.
Insulet's stock has increased by over 50% in the last six months, thanks to strong earnings in the third quarter and the approval of Omnipod 5 for Type 2 diabetes, which opens up new market opportunities. However, the company faces challenges from high market expectations and competition from major players like Medtronic and Abbott, which could impact its future success. While Insulet's financial situation is strong, with growing revenues and profits, the high stock price requires ongoing impressive growth to justify it.
Insulet Corporation, known for its Omnipod® tubeless insulin pump technology, has announced that its management will speak at three investor conferences. These events include the 6th Annual Wolfe Research Healthcare Conference in New York City on November 20, 2024, and the Nasdaq 51st Investor Conference in London on December 10, 2024.
Jim Hollingshead, the CEO of Insulet, appears on 'Closing Bell: Overtime' to talk about the company's earnings, the Apple app for blood sugar testing, and other topics.
Insulet Corporation (PODD) has released the transcript for their Q3 2024 earnings call.
Insulet (PODD) reported quarterly earnings of $0.90 per share, which is higher than the Zacks Consensus Estimate of $0.77 per share. This is an increase compared to earnings of $0.71 per share from the same period last year.
FAQ
- What is the primary business of Insulet?
- What is the ticker symbol for Insulet?
- Does Insulet pay dividends?
- What sector is Insulet in?
- What industry is Insulet in?
- What country is Insulet based in?
- When did Insulet go public?
- Is Insulet in the S&P 500?
- Is Insulet in the NASDAQ 100?
- Is Insulet in the Dow Jones?
- When was Insulet's last earnings report?
- When does Insulet report earnings?
- Should I buy Insulet stock now?